Manifestation of leukoencephalopathy in a patient with advanced non-small cell lung cancer following treatment with gefitinib

被引：2

作者：

Huang Yi-sheng ^{[1
]}

Huang Biao ^{[2
]}

Wu Yi-long ^{[1
]}

机构：

[1] Guangdong Gen Hosp, Guangdong Lung Canc Inst, Guangzhou 510080, Guangdong, Peoples R China

[2] Guangdong Gen Hosp, Dept Radiol, Guangzhou 510080, Guangdong, Peoples R China

来源：

CHINESE MEDICAL JOURNAL | 2011年 / 124卷 / 22期

关键词：

gefitinib; leukoencephalopathy; radiosensitizing; non-small cell lung cancer; RECEPTOR-TYROSINE KINASE; CENTRAL-NERVOUS-SYSTEM; RADIATION; BRAIN; INHIBITOR; NEUROTOXICITY; CHEMOTHERAPY; METHOTREXATE; RADIOTHERAPY; SURVIVAL;

D O I：

10.3760/cma.j.issn.0366-6999.2011.22.043

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The present case is a patient with advanced non-small cell lung cancer (NSCLC) who developed leukoencephalopathy following radiotherapy and gefitinib treatments. There are rarely reports of such incidences because the median survival period of advanced NSCLC is only ten months. The features of leukoencephalopathy in this case were atypical for radiation leukoencephalopathy, so it was suspected that the leukoencephalopathy was associated with gefitinib. Chin Med J 2011;124(22):3834-3837

引用

页码：3834 / 3837

页数：4

共 31 条

[1] Long-term survival in primary CNS lymphoma [J].

Abrey, LE ;

DeAngelis, LM ;

Yahalom, J .

JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (03) :859-863

[2]

BALL WS, 1992, AM J NEURORADIOL, V13, P761

[3] ZD1839 ('Iressa')1,2 as an anticancer agent [J].

Baselga, J ;

Averbuch, SD .

DRUGS, 2000, 60 (Suppl 1) :33-40

[4] Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types [J].

Baselga, J ;

Rischin, D ;

Ranson, M ;

Calvert, H ;

Raymond, E ;

Kieback, DG ;

Kaye, SB ;

Gianni, L ;

Harris, A ;

Bjork, T ;

Averbuch, SD ;

Feyereislova, A ;

Swaisland, H ;

Rojo, F ;

Albanell, J .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (21) :4292-4302

[5]

Bianco C, 2002, CLIN CANCER RES, V8, P3250

[6] High-dose methotrexate for the treatment of primary cerebral lymphomas: Analysis of survival and late neurologic toxicity in a retrospective series [J].

Blay, JY ;

Conroy, T ;

Chevreau, C ;

Thyss, A ;

Quesnel, N ;

Eghbali, H ;

Bouabdallah, R ;

Coiffier, B ;

Wagner, JP ;

Le Mevel, A ;

Dramais-Marcel, D ;

Baumelou, E ;

Chauvin, F ;

Biron, P .

JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (03) :864-871

[7]

BLEYER WA, 1980, RAD DAMAGE NERVOUS S, P155

[8] Diagnosis in oncology - Side effects of chemotherapy - Case 1. Radiation recall dermatitis from gemcitabine [J].

Burstein, HJ .

JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (03) :693-694

[9] ADVERSE-EFFECTS OF BRAIN IRRADIATION CORRELATED WITH MR AND CT IMAGING [J].

CONSTINE, LS ;

KONSKI, A ;

EKHOLM, S ;

MCDONALD, S ;

RUBIN, P .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1988, 15 (02) :319-330

[10] Gefitinib [J].

Culy, CR ;

Faulds, D .

DRUGS, 2002, 62 (15) :2237-2248

← 1 2 3 4 →